The Central drug regulator, DCGA has approved emergency use authorisation of the Russian Vaccine, Sputnik V. It has now become the third vaccine to get emergency use authorisation from the drug regulator after Covishield and Covaxin.
This was informed by the Russian Direct Investment Fund, RDIF which is a sovereign fund body established by the Russian Government and is engaged with the work of worldwide supply of the SPUTNIK V Vaccine. The Vaccine was developed by Gamaleya National Research Institute of Epidemiology and Microbiology last year in Russia.
The clinical trials of SPUTNIK V in India is being done by Dr Reddy’s Lab. The Hyderabad based, multinational Indian pharma company, Dr. Reddy’s Lab has also inked an agreement with the Russian Direct Investment Fund, RDIF for supply of the Russian vaccine in India. The Subject Expert Committee of the Indian drug regulator had yesterday recommended SPUTNIK V for emergency use authorisation.
The vaccine has displayed robust results in its clinical trials in the country. RDIF has claimed an effectiveness of 91.6 per cent for the Sputnik V vaccine. Dr Reddy’s had applied for emergency use of Sputnik-V in February this year.
Support Ethical Journalism. Support The Dispatch
The Dispatch is a sincere effort in ethical journalism. Truth, Accuracy, Independence, Fairness, Impartiality, Humanity and Accountability are key elements of our editorial policy. But we are still not able to generate great stories, because we don’t have adequate resources. As more and more media falls into corporate and political control, informed citizens across the world are funding independent journalism initiatives. Here is your chance to support your local media startup and help independent journalism survive. Click the link below to make a payment of your choice and be a stakeholder in public spirited journalism